ArticleFrontiers in cell and developmental biology2026
Development and clinical validation of a nursing risk prediction model for chemotherapy-induced febrile neutropenia in patients with cancer.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Febrile neutropenia (FN) is one of the most serious yet potentially preventable complications of systemic chemotherapy. However, practical tools that support nursing-led early risk stratification and workflow-ready preventive actions remain limited. Methods: We performed a real-world cohort study including 2,125 patients with cancer receiving systemic chemotherapy at a single institution. Patients were randomly split (7:3) into a derivation cohort (70%) and an internal validation cohort (30%). Candidate predictors were prespecified to ensure bedside nursing assessability and routine clinical availability, incorporating both conventional clinical/laboratory factors and nursing-relevant indicators (e.g., nutritional risk, mucositis, and self-monitoring adherence). Predictors were selected using penalized regression, followed by multivariable logistic modeling to estimate FN risk in the first evaluable chemotherapy cycle. Model performance was assessed by discrimination and calibration, and clinical utility was examined using decision curve analysis. A nomogram and risk-stratified nursing pathways were developed to translate predicted risk into actionable surveillance and preventive care. Results: The final nursing-oriented model showed good discrimination and satisfactory calibration in both the derivation and validation cohorts. Decision curve analysis indicated net benefit across a clinically relevant range of threshold probabilities. Risk stratification based on predicted probabilities was associated with graded increases in FN incidence and adverse clinical outcomes. Conclusion: This nursing-oriented FN prediction model provides individualized early-cycle FN risk estimation and operational risk stratification to support targeted surveillance and preventive nursing interventions. External validation across diverse institutions and nursing documentation systems is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.